Citations

Mayo Clinic

Showing 10 of 108572 citations.

Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors
Sotelo, Carolina , Vallejo-Ardila, Dora L. , Ruíz-Patiño, Alejandro , Rodríguez, July, Isaza, Hernán Carranza , Otero, Jorge, Archila, Pilar , Rojas, Leonardo , Zuluaga, Jairo , Gómez, Cladelis Rubio , García-Robledo, Juan Esteban , Espinosa, Sergio Andrés Mejía , Jaller, Elvira , Cardona, Andrés F. , Sotelo-Rodríguez, Carolina , Vallejo-Ardila, Dora , Carranza, Hernán , Rojas, Leonardo , Rubio, Cladelis , Ordóñez-Reyes, Camila , Garcia-Robledo, Juan Esteban , Mejía, Sergio , Jaller, Elvira , Arrieta, Oscar , Cardona, Andrés F , Pérez, Darwin Andrés Moreno , Carranza, Hernán, Vargas, Carlos, Ordóñez‐Reyes, Camila , Arrieta, Óscar

JCO Global Oncology | January 18, 2024 | Volume: No volume available | Issue: 10 | Pages: No page available

10.1200/go.23.00011 | PMID 38237094 Get It

PURPOSE Multidisciplinary molecular tumor boards (MTBs) decode complex genomic data into clinical recommendations. Although MTBs are well-established in the oncology practice in developed countries, this strategy needs to be better explored in developing countries. Herein, we describe the possible benefits and limitations of the first MTB established in Colombia. METHODS Demographic, clinical, and genomic information was collected between August 2020 and November 2021. By mid-2020, an MTB strategy was created to discuss clinical cases with one or more genomic alterations identified by next-generation sequencing using an open-access virtual platform. We characterized the patient population as benefiting from the recommended treatment option. We assessed the benefits and access to available targeted therapies that have the potential to change clinical management by making recommendations to treating oncologists on the basis of genomic profiling. However, we did not assess the treatment oncologists' compliance with MTB recommendations because they were not intended to replace clinical judgment/standard of care. RESULTS A total of 146 patients were included in the discussions of the MTB. The median age was 59 years, and 59.6% were women. Genomic results prompting a change in therapeutic decisions were obtained in 53.1% of patients (95% CI, 44.9 to 61.3). The most prevalent malignancy was non–small-cell lung cancer (51%). Other malignancies represented 60%, 50%, and 30% of patients with soft-tissue sarcomas, brain tumors, and breast cancer, respectively. CONCLUSION Using an open-access virtual platform, MTBs were feasible in low- and middle-income countries on the basis of the capability to provide the benefits and access to available targeted therapies that are not standard of care. Furthermore, MTB recommendations were made available to the treating oncologist in different locations across Colombia, providing the option to modify clinical management in most of these patients.
Fully Integrated Mixed-Signal Classifier for Cardiovascular Health Monitoring
Bhanushali, Sumukh Prashant , Sadasivuni, Sudarsan , Banerjee, Imon , Banerjee, Imon , Sanchez, Jose, Sanyal, Arindam

2023 IEEE Biomedical Circuits and Systems Conference (BioCAS) | January 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/biocas58349.2023.10388918 Get It

Enhancing Patient Care in Rare Genetic Diseases: An HPO-based Phenotyping Pipeline
Xiao, Yao , Enayati, Moein , Schaeferle, Gavin M., Lanpher, Brendan C. , Klee, Eric W. , Ngufor, Che

2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) | January 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 2754-2760

10.1109/bibm58861.2023.10385978 Get It

Harnessing Transfer Learning for Dementia Prediction: Leveraging Sex-Different Mild Cognitive Impairment Prognosis
Liu, Ziming , Garg, Muskan , Sarkar, Surjodeep , Vassilaki, Maria , Petersen, Ronald C. , Sohn, Sunghwan , St Sauver, Jennifer, Fu, Sunyang , Sauver, Jennifer L. St.

2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) | January 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 2097-2100

10.1109/bibm58861.2023.10385516 | PMID 38404694 Get It

Machine Learning Models for Prediction of Joint Infections Following Hip Replacement Surgery
Sohn, Sunghwan , Kremers, Hilal Maradit , Kremers, Walter K.

2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) | January 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 3053-3058

10.1109/bibm58861.2023.10385421 Get It

Navigating Sex-Specific Disease Dynamics in Incident Dementia
Garg, Muskan , Liu, Xingyi , Vassilaki, Maria , Petersen, Ronald C. , Sohn, Sunghwan , St Sauver, Jennifer, Sauver, Jennifer L. St.

2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) | January 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 4065-4072

10.1109/bibm58861.2023.10385324 | PMID 38404695 Get It

Unveiling an Overlooked Link—Promising Drug Efficacy in Lowering Withdrawal Rates in Cancer Trials—Reply
Hillman, Shauna L., Jatoi, Aminah , Mandrekar, Sumithra J.

JAMA Oncology | January 18, 2024 | Volume: 10 | Issue: 3 | Pages: 411

10.1001/jamaoncol.2023.6437 | PMID 38236585 Get It

Predicting voided computerized physician order entry in oral and maxillofacial surgery inpatients: development and validation of machine learning model
Nathan, John , Arce, Kevin , Nathan, John M., Herasevich, Vitaly

No container title available | January 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3868326/v1 Get It

Abstract Objective The aim of this study is to determine if supervised machine learning algorithms can accurately predict cancelled and self-intercepted computerized physician order entry in oral and maxillofacial surgery inpatients. Methods Data from Electronic Medical Record included patient demographics, comorbidities, procedures, vital signs, laboratory values, and medication orders were retrospectively collected. Predictor variables included patient demographics, comorbidities, procedures, vital signs, and laboratory values. Outcome of interest is if a medication order was voided or not. Data was cleaned and pro1cessed using Microsoft Excel and Python v3.12. Gradient Boosted Decision Trees, Random Forest, K-Nearest Neighbor, and Naïve Bayes were trained, validated, and tested for accuracy of the prediction of voided medication orders. Results 37,546 medication orders from 1,204 patient admissions over 5 years were used for this study included 3,892 (10.4%) medication orders that were voided. Gradient Boosted Decision Trees, Random Forest, K-Nearest Neighbor, and Naïve Bayes had an Area Under the Receiver Operating Curve of 0.802 802 with 95% CI [0.787, 0.825], 0.746 with 95% CI [0.722, 0.765], 0.685 with 95% CI [0.667, 0.699], and 0.505 with 95% CI [0.489, 0.539], respectively. Area Under the Precision Recall Curve was 0.684 with 95% CI [0.679, 0.702], 0.647 with 95% CI [0.638, 0.664], 0.429 with 95% CI [0.417, 0.434], and 0.551 with 95% CI [0.551, 0.552], respectively. Conclusion Gradient Boosted Decision Trees is the best model of the supervised machine learning algorithms with satisfactory performance in validation cohort for predicting voided Computerized Physician Order Entry in Oral and Maxillofacial Surgery inpatients.
Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131
Tevaarwerk, Amyé , Garcia, Sofia F. , Arteaga, Carlos L. , Symmans, W. Fraser , Burnette, Brian L., Makower, Della , Block, Margaret , Morley, Kimberly, Jani, Chirag , Mescher, Craig , Dewani, Shabana J. , Brown‐Glaberman, Ursa, Flaum, Lisa , Sikov, William M. , Rodler, Eve T. , Tevaarwerk, Amye J , Garcia, Sofia F , Sparano, Joseph A , Wagner, Lynne , Symmans, W Fraser , Smith, Karen L. , Zhao, Fengmin , Mayer, Ingrid A. , Park, Ben Ho , Mayer, Erica L. , DeMichele, Angela , Sparano, Joseph A. , Wolff, Antonio C. , Miller, Kathy D. , Wagner, Lynne I.

Cancer | January 18, 2024 | Volume: 130 | Issue: 10 | Pages: 1747-1757

10.1002/cncr.35187 | PMID 38236702 Get It

AbstractBackgroundPatient‐reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment‐associated adverse events (AEs) compared with clinician‐rated AEs. The authors present PROs assessing health‐related quality of life (HRQoL) and treatment‐related neurotoxicity for adjuvant capecitabine versus platinum on the Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) EA1131 trial (ClinicalTrials.gov identifier NCT02445391).MethodsParticipants completed the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy–Breast Cancer Symptom Index (NFBSI‐16) and the Functional Assessment of Cancer Therapy–Gynecologic Oncology Group neurotoxicity subscale (platinum arm only) at baseline, cycle 3 day 1 (C3D1), 6 months, and 15 months. Because of early termination, power was insufficient to test the hypothesis that HRQoL, as assessed by the NFBSI‐16 treatment side‐effect (TSE) subscale, would be better at 6 and 15 months in the capecitabine arm; all analyses were exploratory. Means were compared by using t‐tests or the Wilcoxon rank‐sum test, and proportions were compared by using the χ2 test.ResultsTwo hundred ninety‐six of 330 eligible patients provided PROs. The mean NFBSI‐16 TSE subscale score was lower for the platinum arm at baseline (p = .02; absolute difference, 0.6 points) and for the capecitabine arm at C3D1 (p = .04; absolute difference, 0.5 points), but it did not differ at other times. The mean change in TSE subscale scores differed between the arms from baseline to C3D1 (platinum arm, 0.15; capecitabine arm, −0.72; p = .03), but not from baseline to later time points. The mean decline in Functional Assessment of Cancer Therapy–Gynecologic Oncology Group neurotoxicity subscale scores exceeded the minimal meaningful change (1.38 points) from baseline to each subsequent time point (all p < .05).ConclusionsDespite the similar frequency of clinician‐rated AEs, PROs identified greater on‐treatment symptom burden with capecitabine and complemented clinician‐rated AEs by characterizing patients’ experiences during chemotherapy.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
Cynthia, X. , Sanati, Souzan , Leitch, A. Marilyn , Unzeitig, Gary, Fernández-Martínez, Aranzazu , Fan, Cheng , Gibbs, Richard A. , Dockter, Travis , Hahn, Olwen, Guenther, Joseph M., Caudle, Abigail S. , Crouch, Erika C., Tiersten, Amy , Mita, Monica , Razaq, Wajeeha, Rimawi, Mothaffar F. , Weiss, Anna , Perou, Charles M. , Carey, Lisa A. , Dockter, Travis J, Carey, Lisa A , Perou, Charles M , Rimawi, Mothaffar , Fernandez-Martinez, Aranzazu , Suman, Vera J. , Vij, Kiran R , Anurag, Meenakshi , Hoog, Jeremy , Watson, Mark A. , Hieken, Tina J. , Wang, Yang , Winer, Eric P. , Hunt, Kelly K. , Ellis, Matthew J. , Partridge, Ann H.

JAMA Oncology | January 18, 2024 | Volume: 10 | Issue: 3 | Pages: 362

10.1001/jamaoncol.2023.6038 | PMID 38236590 Get It

Importance Adding fulvestrant to anastrozole (A+F) improved survival in postmenopausal women with advanced estrogen receptor (ER)–positive/ERBB2 (formerly HER2)–negative breast cancer. However, the combination has not been tested in early-stage disease. Objective To determine whether neoadjuvant fulvestrant or A+F increases the rate of pathologic complete response or ypT1-2N0/N1mic/Ki67 2.7% or less residual disease (referred to as endocrine-sensitive disease) over anastrozole alone. Design, Setting, and Participants A phase 3 randomized clinical trial assessing differences in clinical and correlative outcomes between each of the fulvestrant-containing arms and the anastrozole arm. Postmenopausal women with clinical stage II to III, ER-rich (Allred score 6-8 or &amp;gt;66%)/ERBB2-negative breast cancer were included. All analyses were based on data frozen on March 2, 2023. Interventions Patients received anastrozole, fulvestrant, or a combination for 6 months preoperatively. Tumor Ki67 was assessed at week 4 and optionally at week 12, and if greater than 10% at either time point, the patient switched to neoadjuvant chemotherapy or immediate surgery. Main Outcomes and Measures The primary outcome was the endocrine-sensitive disease rate (ESDR). A secondary outcome was the percentage change in Ki67 after 4 weeks of neoadjuvant endocrine therapy (NET) (week 4 Ki67 suppression). Results Between February 2014 and November 2018, 1362 female patients (mean [SD] age, 65.0 [8.2] years) were enrolled. Among the 1298 evaluable patients, ESDRs were 18.7% (95% CI, 15.1%-22.7%), 22.8% (95% CI, 18.9%-27.1%), and 20.5% (95% CI, 16.8%-24.6%) with anastrozole, fulvestrant, and A+F, respectively. Compared to anastrozole, neither fulvestrant-containing regimen significantly improved ESDR or week 4 Ki67 suppression. The rate of week 4 or week 12 Ki67 greater than 10% was 25.1%, 24.2%, and 15.7% with anastrozole, fulvestrant, and A+F, respectively. Pathologic complete response/residual cancer burden class I occurred in 8 of 167 patients and 17 of 167 patients, respectively (15.0%; 95% CI, 9.9%-21.3%), after switching to neoadjuvant chemotherapy due to week 4 or week 12 Ki67 greater than 10%. PAM50 subtyping derived from RNA sequencing of baseline biopsies available for 753 patients (58%) identified 394 luminal A, 304 luminal B, and 55 nonluminal tumors. A+F led to a greater week 4 Ki67 suppression than anastrozole alone in luminal B tumors (median [IQR], −90.4% [−95.2 to −81.9%] vs −76.7% [−89.0 to −55.6%]; P &amp;lt; .001), but not luminal A tumors. Thirty-six nonluminal tumors (65.5%) had a week 4 or week 12 Ki67 greater than 10%. Conclusions and Relevance In this randomized clinical trial, neither fulvestrant nor A+F significantly improved the 6-month ESDR over anastrozole in ER-rich/ERBB2-negative breast cancer. Aromatase inhibition remains the standard-of-care NET. Differential NET response by PAM50 subtype in exploratory analyses warrants further investigation. Trial Registration ClinicalTrials.gov Identifier: NCT01953588